Table 2.
The concentration of simvastatin used in vivo.
| Cancers | Cell lines | Simvastatin Concentration | Medication Method | Results a |
|---|---|---|---|---|
| Glioma | U87MG | 2.5 mg/kg/dayb | s.c. | Positive |
| Human glioblastoma multiforme | GL-26 cells | 1.0 mg/kg/day or 10.0 mg/kg/day | oral | Negative |
| Pulmonary Lymphangioleiomyomatosis | TSC2-null cells from the primary tumors | 100.0 mg/kg/day | oral | Positive |
| Lung Carcinoma | HLMC cells from the primary patients | 50.0 mg/kg/day | oral | Positive |
| Lung Adenocarcinoma | A549 cells | 10.0 mg/kg/day | i.v | Positive |
| Gastric Cancer | SNU-5 cells | 2.1 mg/kg/dayb | i.p. | Positive |
| Hepatocellular Carcinoma | HepG2 cells | 40.0 mg/kg/day | i.p. | Positive |
| Pancreatic Cancer | CAPAN-2 cells | 0.5 mg/kg/day | oral | Positive |
| Pancreatic Ductal Adenocarcinoma | Panc-1 cells from the primary tumors | 20.0 mg/kg/day | i.p. | Positive |
| Colorectal Cancer | SW 480 cells | 6.0 mg/kg/day | oral | Positive |
| Colorectal Cancer | HCT116 or HT29 cells | 50.0 mg/kg/day | oral | Positive |
| Colorectal Cancer | HCT116 p53 +/+ or p53 -/-cells | 20.0 mg/kg/day | i.p. | Positive |
| Renal Cancer | Caki-1-staR cells | 6.7 mg/kg/dayb | i.p. | Negative |
| Renal Cancer | A498 cells | 5.0 mg/kg/day | oral | Positive |
| Prostate Cancer | 22RV1 cells | 25.0 mg/kg/day | i.p. | Positive |
| Prostate Cancer | LAPC-4 cells | 11.0 mg/kg/day b | s.c. | Negative |
| Prostate Cancer | PC-3 cells | 4.0 mg/kg/day | i.p. | Positive |
| Prostate Cancer | PC-3 cells | 2.0 mg/kg/day or 4.0 mg/kg/day | i.p. | Positive |
| Prostate Cancer | PC-3 cells | 2.1 mg/kg/dayor 21.0 mg/kg/day | i.p. | Positive |
| Breast Cancer | MDA-MB-231 cells | 10.0 mg/kg/day | oral | Positive |
| Breast Cancer | MDA-MB-231 cells | 5.0 mg/kg/day | unknown c | Positive |
| Breast Cancer | MDA-MB-231 cells | 200.0 mg/kg/day | oral | Positive |
| Breast Cancer | MDA-MB-231 cells | 5.0 mg/kg/day | i.v. | Positive |
| Osteosarcoma | KHOS or NP cells | 10.0 mg/kg c | unknown c | Positive |
| Pediatric Acute Lymphoblastic Leukemia | specimens of T-ALL patients | 20.0 mg/kg/day | oral | Negative |
| Chronic Myelogenous Leukemia | K562 cells | 1.3 mg/kg/day 2 or 2.0 mg/kg/day b | i.p. | Positive |
| Chronic Myelogenous Leukemia | K562 cells | 7.1 mg/kg/day 2 or14.3 mg/kg/dayb | i.p. | Positive |
aPositive: Simvastatin alone inhibited the progression of cancer; Negative: Simvastatin alone could not inhibit the progression of cancer. bConcentration was converted into the dosage per kilogram per day. cRelevant information was not provided in the article. Subcutaneous injection (s.c.), Intravenous injection (i.v.), Intraperitoneal injection (i.p.).